Drug Trial Radar · NCT00297232
Natalizumab (Tysabri) Re-Initiation of Dosing
Last checked: Nov 20, 2026Latest source record: Jul 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,094
Actual
Start
Mar 2006
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to natalizumab and confirming the safety of switching from interferon (IFN), glatiramer acetate, or other multiple sclerosis (MS) therapies to natalizumab. The primary objective for the long-term treatment period of this study is to evaluate the long-term impact of natalizumab monotherapy on the progression of disability measured by Expanded Disability Status Scale (EDSS) changes over time.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
NatalizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) ProgressionTime frame: up to 480 weeks
- Time to 48-week Confirmed EDSS ProgressionTime frame: up to 480 weeks
- Time to 24-week Confirmed EDSS Improvement Where Baseline ≥ 2.0Time frame: Up to 480 weeks
Locations
112 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Camperdown, Australia
Research Site
Heidelberg, Australia
Research Site
Parkville, Australia
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Diepenbeek, Belgium
Research Site
Melsbroek, Belgium
Research Site
Sijsele, Belgium
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Kingston, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
New York, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Brno, Czechia
Research Site
Brno, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Olomouc, Czechia
Research Site
Ostrava, Czechia
Research Site
Pardubice, Czechia
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Aarhus C, Denmark
Research Site
Copenhagen, Denmark
Research Site
Esbjerg, Denmark
Research Site
Helsinki, Finland
Research Site
Tampere, Finland
Research Site
Turku, Finland
Research Site
Besançon, France
Research Site
Bordeaux, France
Research Site
Clermont-Ferrand, France
Research Site
Créteil, France
Research Site
Dijon, France
Research Site
Lille, France
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.